147 related articles for article (PubMed ID: 35269955)
1. Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
Giraudi PJ; Salvoza N; Bonazza D; Saitta C; Lombardo D; Casagranda B; de Manzini N; Pollicino T; Raimondo G; Tiribelli C; Palmisano S; Rosso N
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269955
[TBL] [Abstract][Full Text] [Related]
2. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
[TBL] [Abstract][Full Text] [Related]
4. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
5. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
6. Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease.
Schwenger KJP; Alali M; Ghorbani Y; Fischer SE; Jackson TD; Okrainec A; Allard JP
Obes Surg; 2023 Jan; 33(1):247-255. PubMed ID: 36464738
[TBL] [Abstract][Full Text] [Related]
7. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
8. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients.
Anty R; Hastier A; Canivet CM; Patouraux S; Schneck AS; Ferrari-Panaia P; Ben-Amor I; Saint-Paul MC; Gugenheim J; Gual P; Iannelli A; Tran A
Obes Surg; 2016 Sep; 26(9):2138-2143. PubMed ID: 26787197
[TBL] [Abstract][Full Text] [Related]
9. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
10. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data.
Gaia S; Campion D; Evangelista A; Spandre M; Cosso L; Brunello F; Ciccone G; Bugianesi E; Rizzetto M
Liver Int; 2015 Aug; 35(8):2027-35. PubMed ID: 25495478
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study.
Sarvestany SS; Kwong JC; Azhie A; Dong V; Cerocchi O; Ali AF; Karnam RS; Kuriry H; Shengir M; Candido E; Duchen R; Sebastiani G; Patel K; Goldenberg A; Bhat M
Lancet Digit Health; 2022 Mar; 4(3):e188-e199. PubMed ID: 35216753
[TBL] [Abstract][Full Text] [Related]
13. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.
Alqahtani SA; Golabi P; Paik JM; Lam B; Moazez AH; Elariny HA; Goodman Z; Younossi ZM
Obes Surg; 2021 May; 31(5):2002-2010. PubMed ID: 33616848
[TBL] [Abstract][Full Text] [Related]
14. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
[TBL] [Abstract][Full Text] [Related]
15. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
16. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
[TBL] [Abstract][Full Text] [Related]
17. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
[No Abstract] [Full Text] [Related]
18. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds.
Meneses D; Olveira A; Corripio R; Del Carmen Méndez M; Romero M; Calvo-Viñuelas I; Herranz L; Vicent D; de-Cos-Blanco AI
Obes Surg; 2020 Jul; 30(7):2538-2546. PubMed ID: 32157523
[TBL] [Abstract][Full Text] [Related]
19. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
[TBL] [Abstract][Full Text] [Related]
20. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.
Ooi GJ; Earnest A; Kemp WW; Burton PR; Laurie C; Majeed A; Johnson N; McLean C; Roberts SK; Brown WA
Int J Obes (Lond); 2018 Nov; 42(11):1900-1911. PubMed ID: 29463916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
